Autopsy report · NCT02633293
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Cause of deathFunding or business, also regulatory or ethics
“Inhaled treprostinil became commercially available in the US following its approval for PH-ILD”
Life of this trial
- Registered 9 months before it started.
- Ran for about 4 years 11 months before it stopped.
- 243 participants enrolled.
- Results were posted on the registry 1 year 4 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2, Phase 3
- Sponsor
- United Therapeutics
- Sponsor type
- Industry
- Conditions
- Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
- Interventions
- Inhaled Treprostinil
- Participants
- 243
- Sites
- 92
- Countries
- Puerto Rico, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.